NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 31, 2024
NGM Biopharmaceuticals, Inc. (NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the initiation of a Phase 1a/1b clinical stud
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
09:11pm, Wednesday, 05'th Feb 2020
Non-alcoholic steatohepatitis, or NASH, is a metabolic disorder caused by a buildup of fat in the liver, leading to liver inflammation and damage. It belongs to a group of conditions called non-alcoho
/PRNewswire/ -- USA News Group – A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that...
Hedge Funds Are Dumping NGM Biopharmaceuticals, Inc. (NGM)
10:43pm, Tuesday, 17'th Dec 2019
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the d
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors
10:00pm, Thursday, 05'th Dec 2019
NGM Biopharmaceuticals, Inc. (NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with
These 3 “Strong Buy” Healthcare Stocks Have 40% Upside — Or More, Says Cowen
11:10pm, Wednesday, 20'th Nov 2019
The world’s population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 and older, with it predicting one out of every six
NGM Biopharmaceuticals Shares March Higher, Can It Continue?
12:21pm, Wednesday, 20'th Nov 2019
As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.
